NATTO: SECOND HALF AND PRELIMINARY FULL YEAR 2017 EARNINGS RELEASE

Oslo, Norway (8th February 2018) - Please find attached the Nattopharma Group Second Half and Preliminary Full Year 2017 Earnings Release.

Financial highlights of 2017 are;

  • Record sales of NOK 66,6 million full year and 36,0 million H2
  • Positive Adj. EBITDA NOK 5,3 million full year and 3,8 million H2
  • Significantly improved product margin:
    • o   49% in H2-2017 vs 41,6% in H2-2016
  • Operating improvement increasing momentum in Q4
  • Positive Net Result of NOK 22,9 million full year and 30,0 million H2 

A presentation will be held via webcast by Dan Rosenbaum and Kjetil Ramsøy at 10 am CET, Thursday 8th February 2018, followed by a Q&A session directly thereafter.

Please follow the below link to join the webcast;

http://webtv.hegnar.no/presentation.php?webcastId=77778707

For more information, please contact:

Kjetil Ramsøy

CFO, NattoPharma

E-mail: kjetil.ramsoy@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

This information is information that NattoPharma ASA (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above at 08:39 pm CET on February 8th, 2018.

Tags:

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.